Biguanide (BG) — Competitive Intelligence Brief

Biguanide (BG) (Biguanide (BG)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

phase 3 Biguanide AMPK, mitochondrial complex I Diabetes Small molecule

Target snapshot

Biguanide (BG) (Biguanide (BG)) — Eli Lilly and Company. Biguanides reduce hepatic glucose production and improve insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Biguanide (BG) TARGET	Biguanide (BG)	Eli Lilly and Company	phase 3	Biguanide	AMPK, mitochondrial complex I
Biguanides (BG)	Biguanides (BG)	Eli Lilly and Company	phase 3	Biguanide	AMPK, mitochondrial complex I
rosiglitazone maleate/metformin hydrochloride	rosiglitazone maleate/metformin hydrochloride	GlaxoSmithKline	marketed	Thiazolidinedione/Biguanide combination	PPAR-γ (rosiglitazone); Complex I of mitochondrial respiratory chain (metformin)
Insulin glargine combined with metformin	Insulin glargine combined with metformin	Sun Yat-sen University	marketed	Insulin + biguanide combination	Insulin receptor (insulin glargine); AMP-activated protein kinase and mitochondrial complex I (metformin)
Metformin, Pioglitazone	Metformin, Pioglitazone	Khyber Medical University Peshawar	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	AMPK (metformin); PPARγ (pioglitazone)
Metformin hydrochoride	Metformin hydrochoride	University of Massachusetts, Worcester	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
Metformin Small Pack	Metformin Small Pack	GlaxoSmithKline	marketed	Biguanide	AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

1. AstraZeneca · 4 drugs in this class
2. Merck Sharp & Dohme LLC · 3 drugs in this class
3. University of Texas Southwestern Medical Center · 2 drugs in this class
4. Mount Sinai Hospital, Canada · 2 drugs in this class
5. GlaxoSmithKline · 2 drugs in this class
6. Eli Lilly and Company · 2 drugs in this class
7. University Magna Graecia · 2 drugs in this class
8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class